An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial

BACKGROUND: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an acceler...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Transl Allergy
Huvudupphovsmän: Chaker, A. M., Al-Kadah, B., Luther, U., Neumann, U., Wagenmann, M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2016
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4736162/
https://ncbi.nlm.nih.gov/pubmed/26839682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0093-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk